戻る
Island Pharmaceuticals Ltd (ILPLF)価格
ILPLF 株価推移チャート
ILPLF 財務
Island Pharmaceuticals Ltd
$0
0%
$0
終値： Jan 16, 16:00:00 GMT-5
$0
0%
$0
アフターマーケット：Jan 16, 20:00:00 GMT-5
収入
貸借対照表
現金の流れ
年次
四半期
ILPLF 収入
金額は百万米ドル単位。会計年度は2月から1月まで。
Follow-Up Questions
Island Pharmaceuticals Ltdの主要な財務諸表は何ですか？
ILPLFの主要な財務比率は何ですか？
Island Pharmaceuticals Ltdの収益はセグメントまたは地域別にどのように分けられていますか？
Island Pharmaceuticals Ltdは収益を上げていますか？
Island Pharmaceuticals Ltdに負債はありますか？
Island Pharmaceuticals Ltdの発行済株式数は何株ですか？
主要データ
前終値
--
始値
--
当日レンジ
-
52週レンジ
-
取引高
--
平均取引高
--
1株当たり利益(TTM)
--
配当利回り
--
時価総額
--
ILPLFとは何ですか？
Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-04-13. The firm is focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Its lead asset is ISLA-101, a drug with a safety profile being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. While ISLA-101 is an oral formulation, the Company is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The firm operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.